Stem Cells A Technology Assessment June2009

June 1 st , 2009 STEM CELLS Jie He Tony Jia Ji Young Lee Andy Yen

HISTORICAL PERSPECTIVE AND SCIENTIFIC BACKGROUND ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SCIENTIFIC BACKGROUND ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

RESEARCH METHODOLOGY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

LIST OF INTERVIEWS CONDUCTED ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DEVELOPMENT CYCLE ,[object Object],[object Object],[object Object],[object Object],[object Object],Research Testing/Approval Commercialization

DEVELOPMENT - RESEARCH ,[object Object]

DEVELOPMENT - RESEARCH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DEVELOPMENT – TESTING AND APPROVAL ,[object Object],[object Object],[object Object],How can FDA regulate biotech they have no experience in? GMP Labs Researchers must educate the FDA Physician Initiated Trials

COMMERCIALIZATION ,[object Object],[object Object],[object Object],[object Object],[object Object]

COMMERCIALIZATION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

COMMERCIALIZATION ,[object Object]

COMMERCIALIZATION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

POTENTIAL MARKETS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DRIVERS ,[object Object],[object Object],[object Object],[object Object],[object Object]

HOW BIG AND THE NEXT BIG THING ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

IPS CELLS ,[object Object],[object Object],[object Object],Advantages Disadvantages Not Limited by Existing Cell Lines Low Efficiency Can be Derived Universally High Cost Genetic Compatability Very New

MACULAR DEGENERATION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Age Percentage Afflicted 66-74 10% 75-85 30%

Advanced Melanoma ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ROADBLOCKS/RISKS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CONCLUSIONS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Stem Cells A Technology Assessment June2009

Recomendados

Recomendados

Más contenido relacionado

Destacado

Destacado (8)

Similar a Stem Cells A Technology Assessment June2009

Similar a Stem Cells A Technology Assessment June2009 (20)

Más de roke

Más de roke (18)

Último

Último (20)

Stem Cells A Technology Assessment June2009